ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1810

Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine

Anne Margrethe Troldborg1, Annette Hansen2, Kristian Stengaard-Pedersen2 and Steffen Thiel2, 1Aarhus University Hospital, Arhus, Denmark, 2Aarhus University, Aarhus, Denmark

Meeting: ACR Convergence 2020

Keywords: complement, Disease Activity, innate immunity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Mortality in patients with systemic lupus erythematosus (SLE) is significantly higher than in the general population. Treatment of SLE patients has improved, however, a majority of patients still experience symptoms like fatigue, pain and cognitive deficits even when they are clinically evaluated to have low disease activity (LDA) or being in remission. Immunosuppressants are tapered after clinical remission and patients are typically continued on hydroxychloroquine (HCQ).

Activation of the complement system is evident in most SLE patients with active disease. This is usually assessed by low C3 or C4 as a proxy for complement activation (CA). When levels normalize or stabilize, we assume CA has been controlled.

The aim of this project is to examine if SLE patients in remission or with LDA have ongoing CA. This is investigated by measuring the C3 breakdown product C3dg. In addition, we show that in vitro HCQ does not inhibit any of the CA pathways.

Methods: In 166 SLE patients and 145 age and gender-matched controls we measured the C3 breakdown product C3dg (37 kDa fragment), which is only present after activation of C3. Disease activity was assessed using SLEDAI-2K, LLDAS, PGA and remission criteria (SLEDAI-2K=0, corticosteroid-free and immunosuppressant-free, HCQ allowed). The association between CA measured by C3dg and disease activity was estimated. Further, we examined the inhibitory effect of HCQ on CA in vitro in erythrocyte cell lysis assays and by measuring deposition of activation fragments of C3 and C4 on relevant surfaces in microtiter wells, i.e. examining activation through the lectin, the classical and the alternative pathway.

Results: In this cross-sectional cohort of SLE patients the median SLEDAI-score was 4 (range 0-14), median PGA was 1 (range 0-3), 61.4 % of patients were in LLDAS (102/166) and 7.8% were in complete remission (13/166).

C3dg was significantly higher in SLE patients than in controls (p< 0.0001), whereas no significant difference was observed for C3 (p=0.67). Ongoing CA was seen in all SLE patients independently of disease activity assessment (SLEDAI-2K, PGA, LLDAS and PGA). No difference was observed between patients treated or not treated with HCQ (p=0.07). Physiological and supraphysiological concentrations of HCQ did not inhibit CA through any of the complement pathways (fig.1) or in erythrocyte cell lysis assays.

Conclusion: SLE patients have ongoing CA even when our disease assessments scores show remission or LDA.

CA is not affected by HCQ treatment in patients, which in most cases is the drug-of-choice for SLE patients in remission. This is supported by our in vitro studies demonstrating that HCQ does not inhibit CA.

Our current disease activity scores do not include the best measures of biochemically active disease like CA measures. Ongoing CA is not captured by validated clinical disease activity scores and could be an explanation for persistent symptoms reported by many patients and potentially one of the pathogenic mechanisms leading to increased mortality in SLE.

Fig.1: No inhibition of complement activation by hydroxychloroquine in vitro (HCQ).


Disclosure: A. Troldborg, None; A. Hansen, None; K. Stengaard-Pedersen, None; S. Thiel, None.

To cite this abstract in AMA style:

Troldborg A, Hansen A, Stengaard-Pedersen K, Thiel S. Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/complement-activation-in-systemic-lupus-erythematosus-patients-with-low-disease-activity-is-not-inhibited-by-hydroxychloroquine/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/complement-activation-in-systemic-lupus-erythematosus-patients-with-low-disease-activity-is-not-inhibited-by-hydroxychloroquine/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology